Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Europe’s pharmaceutical policy choices – And what the United States stands to learn
18 March 2026
A recent policy discussion on Capitol Hill hosted by We Work For Health examined the lessons the United States might draw from Europe’s experience with pharmaceutical pricing and innovation. As a participant, my key takeaways focused on understanding the trade-offs underpinning EU and UK drug pricing policy and the broader impact on innovation for both sides of the Atlantic.
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
Rare diseases may affect only a small number of people, but together they impact an estimated 300–400 million people worldwide — and only around 5% have an approved treatment. As global attention grows, including the WHO’s upcoming 10-year Global Action Plan, it is important to understand how regulation, HTA, and pricing policies across the UK, EU, and US influence the development of orphan medicines and access for patients.
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
OHE’s submission to a parliamentary inquiry on UK drug shortages
6 October 2025
The following is an extract from OHE’s written submission to parliament focused on diversifying suppliers and recognising the value of treatment alternatives to mitigate this issue.
The Trump Administration’s US Drug Pricing Proposal – What will happen next?
12 June 2025
This is the second in our series of Insights considering the implications of President Trump’s Executive Order on ‘Most Favoured Nation’ drug pricing. We know that…
Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
5 June 2025
Join us for an online CERSI-PGx Health Economics Workshop on 10 June 2025, from 13:00–17:00 BST, with experts from NHS England, NICE, the University of Manchester, and Bangor University.
GLP-1 Receptor Agonists: Shifting Obesity Management
12 May 2025
The glucagon-like peptide-1 (GLP-1) receptor agonist market is experiencing rapid growth, with more than 150 drug candidates currently in development as reported by Research & Markets,…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting treatment options. Our report explores how supplier diversity can enhance healthcare resilience and drive innovation, with actionable recommendations for policymakers.
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
A critique of the recent EEPRU paper